Drug intelligence / Profile preview

janagliflozin

Development stage: Phase 3
Lead developer: Sihuan Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Janagliflozin is a small molecule sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Sihuan Pharmaceutical Holdings Group for the treatment of type 2 diabetes mellitus. It works by inhibiting SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels. Janagliflozin has been approved in China for both monotherapy and combination therapy in type 2 diabetes[3][7]. Clinical trials have demonstrated its efficacy in improving glycemic control in patients inadequately controlled with metformin or as monotherapy[1][5].

Brand names: Huiyoujing
Other names: janagliflozin1800115-22-3

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on janagliflozin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on janagliflozin.

Explore the full profile